Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Stocks opened and closed in positive territory, though the path to the finish line was choppy. A mixed reading on wholesale ...

Entegris manufactures the specialized containers and filters, called FOUPS (Front-Opening-Unified Pods) that transport and ...

In 2011, a 1940s-era plane crashed into a box-seat area in front of the grandstand ... In 2021, Health Canada announced new names for the Pfizer-BioNTech, Moderna and Oxford-AstraZeneca COVID-19 ...

Still, both Pfizer and Moderna have said that their new vaccines can produce stronger ... everything you need is in the box.

Topics included how the… Moderna CEO Stéphane Bancel testified on the increase in price for the company’s COVID-19 vaccine before the Senate Heal… Health care executives testified on ...

Trump safe after second assassination attempt as election nears, Bridgewater bought Microsoft stock and sold Apple last ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...